Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Tempest Therapeutics ( (TPST) ).
On May 6, 2026, Tempest Therapeutics reported new clinical data at the ISCT 2026 meeting in Dublin from its lead dual-targeting CAR-T candidate TPST-2003, showing a 100% complete response rate among 15 CAR-T-naïve efficacy evaluable patients across two Phase 1 trials in relapsed or refractory multiple myeloma and POEMS syndrome. The company highlighted a favorable safety profile with no grade 3 or higher cytokine release syndrome or ICANS, a median progression-free survival of 23.1 months in multiple myeloma across studies, and one of the largest available datasets for a CD19/BCMA dual-targeting CAR-T, bolstering its case to seek FDA discussions on a potential U.S. registrational study and strengthening its positioning in next-generation cell therapy for high-risk hematologic cancers.
Across three studies run with partner Novatim in China, a total of 44 patients have been treated with TPST-2003, including robust activity in patients with extramedullary disease and complete normalization of VEGF levels in all evaluable POEMS patients as of the January 31, 2026 cutoff. These results suggest that TPST-2003’s parallel-structure dual-targeting architecture may deliver deeper and more durable responses than first-generation single-target CAR-T therapies in heavily pretreated myeloma and rare plasma cell disorders, with potential strategic implications for Tempest’s global development plans and competitive outlook in the CAR-T market.
The most recent analyst rating on (TPST) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue losses, historical cash burn, and a weakened balance sheet) and only modest technical strength. Positive corporate events (encouraging trial data and partner-funded pipeline) provide some upside, but valuation signals are limited by negative earnings and no dividend.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, Calif., focused on developing advanced chimeric antigen receptor T-cell (CAR-T) therapies to treat cancer. Its lead program, TPST-2003, is an autologous dual-targeting CD19/BCMA CAR-T therapy being co-developed with partner Novatim Immune Therapeutics, with Tempest holding exclusive rights outside China, India, Turkey and Russia.
Average Trading Volume: 190,733
Technical Sentiment Signal: Sell
Current Market Cap: $30.27M
Find detailed analytics on TPST stock on TipRanks’ Stock Analysis page.